Inventor · disambiguated record
Haixia Liu
Also filed as: LIU HAIXIA
14 granted patents·28 pending applications·66 citations·filing 2013–2025
89Inventor score
Files withHOFFMANN LA ROCHE30ALLERGAN INC8GLUETACS THERAPEUTICS SHANGHAI CO LTD1GZ CEDICINE BIOTECH CO LTD1UNIV CALIFORNIA1
Top patents by PatentIndex Score
42 records- 0194US11285134B2Presbyopia treatmentsALLERGAN INC·Filed 2020·Granted Mar 29, 2022·5 cites·36 claims
- 0294US9447086B26-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2013·Granted Sep 20, 2016·34 cites·5 claims
- 0393US10610518B2Presbyopia treatmentsALLERGAN INC·Filed 2019·Granted Apr 7, 2020·17 cites·20 claims
- 0482US2024285673A1Eye drop formulation with enhanced properties by combining sodium hyaluronate with carboxymethylcelluloseALLERGAN INC·Filed 2024·Application pending·0 cites
- 0580US9266904B26-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2014·Granted Feb 23, 2016·5 cites·23 claims
- 0680US2024382462A1Presbyopia treatmentsALLERGAN INC·Filed 2024·Application pending·0 cites
- 0779US9758530B26-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2016·Granted Sep 12, 2017·3 cites·14 claims
- 0875US12247036B2Tricyclic compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2024·Granted Mar 11, 2025·0 cites·27 claims
- 0975US11713327B2Heteroaryl heterocyclyl compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2019·Granted Aug 1, 2023·1 cites·17 claims
- 1074US10562905B2Carboxy tetrahydropyrazolopyrazine compounds for the treatment of infectious diseasesHOFFMANN LA ROCHE·Filed 2019·Granted Feb 18, 2020·1 cites·6 claims
- 1173US2022241245A1Presbyopia treatmentsALLERGAN INC·Filed 2022·Application pending·0 cites
- 1272US2022096531A1Eye drop formulation with enhanced properties by combining sodium hyaluronate with carboxymethylcelluloseALLERGAN INC·Filed 2021·Application pending·0 cites
- 1368US2025257075A1Macrocyclic inhibitors of kras for the treatment of cancerHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1466US2025074913A1Pyrazole derivatives as sting agonistsHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1563US2025206761A1Haloindole macrocyclic compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1659US2025376482A1Tricyclic compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 1758US2014221309A1Eye drop formulation with enhanced properties by combining sodium hyaluronate with carboxymethylcelluloseALLERGAN INC·Filed 2014·Application pending·0 cites
- 1857US2025163072A1Macrocyclic compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1957US2020181156A1Carboxy tetrahydropyrazolopyrazine compounds for the treatment of infectious diseasesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2053US2013267517A1Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infectionHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 2153US2016235780A1Eye drop formulation with enhanced properties by combining sodium hyaluronate with carboxymethylcelluloseALLERGAN INC·Filed 2016·Application pending·0 cites
- 2253US2025144223A1Protein degradation compound based on nampt target protein and application thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 2352US12252484B2Pyrazolopyridine compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2018·Granted Mar 18, 2025·0 cites·17 claims
- 2452US2022395496A1Piperidinyl amine compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2552US2021269451A1Pyridinyl heterocyclyl compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2651US9856247B24-methyl-dihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2015·Granted Jan 2, 2018·0 cites·18 claims
- 2751US2022363665A1Quinoline compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2849US10604527B2Pyrazine compounds for the treatment of hepatitis B infectionHOFFMANN LA ROCHE·Filed 2018·Granted Mar 31, 2020·0 cites·15 claims
- 2948US10183954B2Oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infectionHOFFMANN LA ROCHE·Filed 2017·Granted Jan 22, 2019·0 cites·30 claims
- 3048US2022340597A1Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3147US2023203022A1Heterocycle and glutarimide skeleton-based compound and applications thereofUNIV SHANGHAI TECHNOLOGY·Filed 2021·Application pending·0 cites
- 3246US2021395239A1Heterocyclyl compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3346US2021300924A15-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosusHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3445US2025250284A1Macrocycle compounds useful as kras inhibitorsHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 3544US10597380B2Pyridazinone-based broad spectrum anti-influenza inhibitorsHOFFMANN LA ROCHE·Filed 2018·Granted Mar 24, 2020·0 cites·42 claims
- 3644US2022339197A1Use of hematopoietic stem cells in preparation of formulation for treating viral diseasesGZ CEDICINE BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 3744US2022112187A1Pyrazolopyridine amine compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3844US2025268894A1Macrocycle compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 3942US2021253575A1Pyrrolidine amine compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 4042US2021323977A1Pyrrolidinyl amide compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 4141US10000512B2Compounds for the treatment of infectious diseasesHOFFMANN LA ROCHE·Filed 2017·Granted Jun 19, 2018·0 cites·21 claims
- 4234US2017275249A1Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferaseUNIV CALIFORNIA·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Haixia Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →